Matrix metalloproteinases that associate with and cleave bone morphogenetic protein-2 in vitro are elevated in hypertrophic fracture nonunion tissue

Journal of Orthopaedic Trauma

Volumn 24, Issue 9, 2010, Pages 557-563

  Fajardo, Marc ^a   Liu, Chuan Ju ^a   Ilalov, Kirill ^a   Egol, Kenneth A ^a  

^a NYU HOSPITAL FOR JOINT DISEASES   (United States)

Author keywords

ADAMTS; bone morphogenetic protein; delayed union; fracture healing; matrix metalloproteinase; nonunion; tissue inhibitor of metalloproteinase

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; DISINTEGRIN; MACROPHAGE ELASTASE; MATRILYSIN; MESSENGER RNA; TISSUE INHIBITOR OF METALLOPROTEINASE;

ARTICLE; CALLUS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FRACTURE NONUNION; GENE EXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; MALE; PRIORITY JOURNAL; PROTEIN INTERACTION;

ADULT; AGED; AGED, 80 AND OVER; BONE MORPHOGENETIC PROTEIN 2; BONY CALLUS; CALCIFICATION, PHYSIOLOGIC; CELLS, CULTURED; FEMALE; FRACTURE HEALING; FRACTURES, UNUNITED; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; PILOT PROJECTS; RNA, MESSENGER;

EID: 77956235934     PISSN: 08905339     EISSN: None     Source Type: Journal    
DOI: 10.1097/BOT.0b013e3181ed294c     Document Type: Article

References (12)

1. Gerstenfeld LC, Al-Ghawas M, Alkhiary YM, et al. Selective and nonselective cyclooxygenase-2 inhibitors and experimental fracture-healing. Reversibility of effects after short-term treatment. J Bone Joint Surg Am. 2007;89:114-125.
2. Schindeler A, McDonald MM, Bokko P, et al. Bone remodeling during fracture repair: The cellular picture. Semin Cell Dev Biol. 2008; 19:459-466.
3. Yamagiwa H, Tokunaga K, Hayami T, et al. Expression of metal-loproteinase-13 (Collagenase-3) is induced during fracture healing in mice. Bone. 1999;25:197-203.
4. Nuttall RK, Pennington CJ, Taplin J, et al. Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. Mol Cancer Res. 2003; 1:333-345.
5. Porter S, Scott SD, Sassoon EM, et al. Dysregulated expression of adamalysin-thrombospondin genes in human breast carcinoma. Clin Cancer Res. 2004;10:2429-2440.
6. Oshima T, Kunisaki C, Yoshihara K, et al. Clinicopathological significance of the gene expression of matrix metalloproteinases and reversion-inducing cysteine-rich protein with Kazal motifs in patients with colorectal cancer: MMP-2 gene expression is a useful predictor of liver metastasis from colorectal cancer. Oncol Rep. 2008; 19:1285-1291.
7. Davidson RK, Waters JG, Kevorkian L, et al. Expression profiling of metalloproteinases and their inhibitors in synovium and cartilage. Arthritis Res Ther. 2006;8:R124.
8. Clark IM, Parker AE. Metalloproteinases: their role in arthritis and potential as therapeutic targets. Expert Opin Ther Targets. 2003; 7:19-34.
9. Wang K, Vishwanath P, Eichler GS, et al. Analysis of fracture healing by large-scale transcriptional profile identified temporal relationships between metalloproteinase and ADAMTS mRNA expression. Matrix Biol. 2006;25:271-281.
10. Uusitalo H, Hiltunen A, Soderstrom M, et al. Expression of cathepsins B, H, K, L, and S and matrix metalloproteinases 9 and 13 during chondrocyte hypertrophy and endochondral ossification in mouse fracture callus. Calcif Tissue Int. 2000;67:382-390.
11. Ortega N, Behonick DJ, Colnot C, et al. Galectin-3 is a downstream regulator of matrix metalloproteinase-9 function during endochondral bone formation. Mol Biol Cell. 2005;16:3028-3039.
12. Kosaki N, Takaishi H, Kamekura S, et al. Impaired bone fracture healing in matrix metalloproteinase-13 deficient mice. Biochem Biophys Res Commun. 2007;354:846-851.